Literature DB >> 22638844

Limited sampling strategy models for estimating the AUC of gliclazide in Chinese healthy volunteers.

Ji-Han Huang1, Kun Wang, Xiao-Hui Huang, Ying-Chun He, Lu-Jin Li, Yu-Cheng Sheng, Juan Yang, Qing-Shan Zheng.   

Abstract

The aim of this work is to reduce the cost of required sampling for the estimation of the area under the gliclazide plasma concentration versus time curve within 60 h (AUC0-60t ). The limited sampling strategy (LSS) models were established and validated by the multiple regression model within 4 or fewer gliclazide concentration values. Absolute prediction error (APE), root of mean square error (RMSE) and visual prediction check were used as criterion. The results of Jack-Knife validation showed that 10 (25.0 %) of the 40 LSS based on the regression analysis were not within an APE of 15 % using one concentration-time point. 90.2, 91.5 and 92.4 % of the 40 LSS models were capable of prediction using 2, 3 and 4 points, respectively. Limited sampling strategies were developed and validated for estimating AUC0-60t of gliclazide. This study indicates that the implementation of an 80 mg dosage regimen enabled accurate predictions of AUC0-60t by the LSS model. This study shows that 12, 6, 4, 2 h after administration are the key sampling times. The combination of (12, 2 h), (12, 8, 2 h) or (12, 8, 4, 2 h) can be chosen as sampling hours for predicting AUC0-60t in practical application according to requirement.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22638844     DOI: 10.1007/s13318-012-0096-7

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  14 in total

1.  Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.

Authors:  N Frey; C Laveille; M Paraire; M Francillard; N H G Holford; Roeline Jochemsen
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

2.  Pharmacokinetics and bioequivalence evaluation of gliclazide/metformin combination tablet and equivalent doses of gliclazide and metformin in healthy Korean subjects.

Authors:  H Y Cho; H Yoon; Y C Lim; Y B Lee
Journal:  Int J Clin Pharmacol Ther       Date:  2009-12       Impact factor: 1.366

3.  A limited sampling strategy for the measurement of cyclosporine AUC.

Authors:  A Johnston; I Sketris; J T Marsden; C G Galustian; T Fashola; D Taube; J Pepper; D W Holt
Journal:  Transplant Proc       Date:  1990-06       Impact factor: 1.066

4.  Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients.

Authors:  Yu Zicheng; Zhou Peijun; Xu Da; Wang Xianghui; Chen Hongzhuan
Journal:  Br J Clin Pharmacol       Date:  2006-10       Impact factor: 4.335

5.  A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.

Authors:  Magali Bolon-Larger; Valérie Chamouard; Françoise Bressolle; Roselyne Boulieu
Journal:  Ther Drug Monit       Date:  2007-02       Impact factor: 3.681

Review 6.  Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.

Authors:  B Holmes; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

7.  Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation.

Authors:  C Monchaud; A Rousseau; F Leger; O J David; J Debord; T Dantoine; P Marquet
Journal:  Eur J Clin Pharmacol       Date:  2003-03-06       Impact factor: 2.953

8.  Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes.

Authors:  T M Davis; F Daly; J P Walsh; K F Ilett; J P Beilby; L J Dusci; P H Barrett
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

9.  IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies.

Authors:  L Lee Dupuis; Cathryn Sibbald; Tal Schechter; Marc Ansari; Adam Gassas; Yves Théorêt; Nastya Kassir; Martin A Champagne; John Doyle
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

10.  Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.

Authors:  Laura Dickinson; David Back; Anton Pozniak; Saye Khoo; Marta Boffito
Journal:  Ther Drug Monit       Date:  2007-06       Impact factor: 3.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.